Literature DB >> 1989792

Effect of ethanol on the efficacy of nasal continuous positive airway pressure as a treatment for obstructive sleep apnea.

R B Berry1, M M Desa, R W Light.   

Abstract

The effect of ethanol ingestion on the efficacy of nasal continuous positive airway pressure (nasal CPAP) as a treatment for the obstructive sleep apnea (OSA) syndrome was studied in ten obese male subjects undergoing this therapy. On the first night of polysomnography, the lowest level of CPAP that maintained airway patency was determined (critical level). On the second (control) night (C), subjects slept the entire night on this level of CPAP. On the third night (E), subjects ingested either 1.5 ml/kg (part A, N = 6) or 2.0 ml/kg (part B, N = 4) of 50 percent ethanol (100 proof vodka) over one half-hour starting 1 h before bedtime. A serum ethanol level was obtained at bedtime (part A: 63.7 +/- 17.3 mg/dl; part B: 108.6 +/- 20.6 mg/dl), and subjects were monitored on the critical level of CPAP. Comparison of nights C and E for parts A + B showed no difference in total sleep time (TST) or the amount of different sleep stages as an absolute time or a percentage of TST except that there was more stage 2 (as a percent of TST) on E nights. The apnea + hypopnea index and C and E nights did not differ and was quite low (3.6 +/- 3.7/h vs 1.9 +/- 2.7/h). Similarly, ethanol ingestion did not increase the number of desaturations to at or below 90 and 85 percent, or lower the mean arterial oxygen saturation in NREM or REM sleep. Analysis of parts A and B separately also showed no differences with respect to the apnea + hypopnea index or the number of desaturations on control and ethanol nights. We conclude that acute moderate ethanol ingestion does not decrease the efficacy of an optimum level of nasal CPAP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989792     DOI: 10.1378/chest.99.2.339

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Perioperative risks and their management in patients with sleep-related breathing disorders.

Authors:  Harald V Genzwuerker; Juergen Meinhardt
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2006-10-05

2.  Upper Airway Elasticity Estimation in Pediatric Down Syndrome Sleep Apnea Patients Using Collapsible Tube Theory.

Authors:  Dhananjay Radhakrishnan Subramaniam; Goutham Mylavarapu; Keith McConnell; Robert J Fleck; Sally R Shott; Raouf S Amin; Ephraim J Gutmark
Journal:  Ann Biomed Eng       Date:  2015-08-28       Impact factor: 3.934

Review 3.  Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea.

Authors:  R R Grunstein
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

4.  Prevalence of sleep apnea in HRH Princess Maha Chakri Srinthorn Medical Center, Thailand.

Authors:  Chairat Neruntarat; Suprapol Chantapant
Journal:  Sleep Breath       Date:  2010-09-17       Impact factor: 2.816

5.  Effect of moderate alcohol intake on nocturnal sleep respiratory parameters in healthy middle-aged men.

Authors:  Ichiro Izumi; Ali Nasermoaddeli; Michikazu Sekine; Sadanobu Kagamimori
Journal:  Environ Health Prev Med       Date:  2005-01       Impact factor: 3.674

6.  Association of alcohol consumption and sleep disordered breathing in men and women.

Authors:  Paul E Peppard; Diane Austin; Richard L Brown
Journal:  J Clin Sleep Med       Date:  2007-04-15       Impact factor: 4.062

7.  Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea.

Authors:  Clete A Kushida; Alejandro Chediak; Richard B Berry; Lee K Brown; David Gozal; Conrad Iber; Sairam Parthasarathy; Stuart F Quan; James A Rowley
Journal:  J Clin Sleep Med       Date:  2008-04-15       Impact factor: 4.062

8.  Obstructive sleep apnea syndrome: natural history, diagnosis, and emerging treatment options.

Authors:  Tarek Gharibeh; Reena Mehra
Journal:  Nat Sci Sleep       Date:  2010-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.